- Home
- BLND vs OTLK Comparison
BLND vs OTLK Comparison
Compare BLND & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLND | OTLK |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.6M | 249.6M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BLND | OTLK |
|---|---|---|
| Price | $1.14 | $0.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $2.96 | ★ $5.03 |
| AVG Volume (30 Days) | 1.4M | ★ 3.9M |
| Earning Date | 11-05-2026 | 12-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.33 | 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,585,000.00 | $8,146,123.00 |
| Revenue This Year | $3.71 | N/A |
| Revenue Next Year | $9.11 | $6,355.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.88 | $0.16 |
| 52 Week High | $3.44 | $2.54 |
Technical Indicators
Market Signals| Indicator | BLND | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 52.75 | 37.19 |
| Support Level | $0.88 | $0.40 |
| Resistance Level | $1.87 | $0.53 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 75.62 | 31.77 |
Price Performance
Historical ComparisonAbout BLND Blend Labs Inc.
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.